#### **BRIEF COMMUNICATION**





# Two new glutarimide antibiotics from Streptomyces sp. HS-NF-780

Xue-Li Zhao<sup>1</sup> · Han Wang<sup>1</sup> · Zheng-Lian Xue<sup>2</sup> · Jian-Song Li<sup>3</sup> · Huan Qi<sup>3</sup> · Hui Zhang<sup>3</sup> · Tian Zhao<sup>1</sup> · Ji-Dong Wang<sup>2,3</sup> · Wen-Sheng Xiang<sup>1</sup>

Received: 27 October 2018 / Revised: 8 January 2019 / Accepted: 11 January 2019 / Published online: 29 January 2019 © The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2019

## Abstract

Two new glutarimide antibiotics, 9-methylstreptimidone  $2-\alpha$ -D-glucopyranoside (1), and hydroxyiso-9-methylstreptimidone (2), along with a known compound, 9-methylstreptimidone (3), have been isolated from the broth of *Streptomyces* sp. HS-NF-780. Their structures were determined on the basis of spectroscopic analysis, including 1D and 2D NMR techniques as well as ESI-MS and comparison with data from the literature. By modified Mosher's method and acid hydrolysis, the absolute configurations of compounds 1 and 2 were established. Compounds 1 and 2 exhibited moderate cytotoxic activity.

The antibiotics of the glutarimide group are structurally characterized by the presence of glutarimide ring bearing a side chain at the 1-position [1]. A number of distinct substances belonging to this class such as 9-methylstreptimidones [2], cycloheximide [3, 4], and migrastatin [5, 6] have been isolated from various species of Streptomyces [7]. Among them, 9-methylstreptimidone showed strong inhibitory activity against yeasts and filamentous fungi [1]. Besides, 9-methylstreptimidone inhibited NO production and iNOS expression in LPS-stimulated RAW264.7 cells, and induced apoptosis in Jurkat cells and adult T-cell leukemia cells, similar to other NF- $\kappa$ B inhibitors [8]. In the course of our screening program for novel microbe-derived bioactive secondary metabolites, two new glutarimide derivatives named 9-methylstreptimidone  $2-\alpha$ -D-glucopyranoside (1) and hydroxyiso-9-methylstreptimidone (2), along with a known

**Supplementary information** The online version of this article (https://doi.org/10.1038/s41429-019-0143-6) contains supplementary material, which is available to authorized users.

☐ Ji-Dong Wang jdwang@hisunpharm.com

Wen-Sheng Xiang xiangwensheng@neau.edu.cn

- <sup>1</sup> Life Science and Biotechnology Research Center, School of Life Science, Northeast Agricultural University, Harbin, China
- <sup>2</sup> College of Biochemical Engineering, Anhui Polytechnic University, Wuhu, China
- <sup>3</sup> Zhejiang Key Laboratory of Antifungal Drugs, Zhejiang Hisun Pharmaceutical Co., Ltd, Taizhou, China

compound, 9-methylstreptimidone (**3**) (Fig. 1), were isolated from the culture broth of *Streptomyces* sp. HS-NF-780. In this paper, we describe the fermentation, isolation, structure elucidation, and bioactivity of the two new compounds.

The producing strain HS-NF-780 was isolated from a soil sample collected from Linyi, Shandong province, China using the standard dilution plate method. The strain was identified as the genus *Streptomyces* because its 16S rRNA sequence (accession no: MH362834 in the GenBank) exhibited a high-sequence similarity of 100% with that of *Streptomyces* sp. NEAU-BGG209 (accession no: MG820043).

Strain HS-NF-780 was grown and maintained for 7 days at 28 °C on the YMS medium consisting of yeast extract 4.0 g, malt extract 10.0 g, glucose 4.0 g, CoCl<sub>2</sub>·6H<sub>2</sub>O 0.005 g and agar 20.0 g in 1.01 tap water at pH 7.0. The stock culture was transferred into 11 Erlenmeyer flasks containing 250 ml of the seed medium and incubated at 28 ° C for 48 h on a rotary shaker at 250 r.p.m. The seed medium was composed of glucose 4.0 g, malt extract 10.0 g and yeast extract 4.0 g in 1.01 tap water, pH 7.0. All of the media were sterilized at 121 °C for 20 min. The seed culture (5%) was transferred into 11 Erlenmeyer flasks containing 25% volume of production medium. The production medium was composed of glucose 1%, soluble starch 4%, yeast extract 0.4%, malt extract 1%, CaCO<sub>3</sub> 0.2%, FeSO<sub>4</sub>·7H<sub>2</sub>O 0.1%, ZnSO<sub>4</sub>·7H<sub>2</sub>O 0.1%, and MnCl<sub>2</sub>·4H<sub>2</sub>O 0.1% at pH 7.2-7.4. The flasks were incubated at 28 °C for 7 days, shaken at 250 r.p.m.

The final 201 fermentation broth was filtered to separate mycelial cake and supernatant. The mycelial cake was washed with water (31) and subsequently extracted with




Fig. 1 Structures of compounds 1, 2, and 3

MeOH (31) and the supernatant was subjected to a Diaion HP-20 resin (Mitsubushi Chemical, Tokyo, Japan) column eluting with 95% EtOH (51). The MeOH extract and the EtOH eluents were evaporated under reduced pressure at 55 °C to yield the crude extract. The crude extract was chromatographed on a silica gel (Qingdao Haiyang Chemical Group, Qingdao, China; 100-200 mesh) column and successively eluted with a stepwise gradient of CHCl<sub>3</sub>/ MeOH (100:0-50: 50, v/v) to give three fractions (Fr.1-Fr.3) based on the TLC profiles. TLC was performed on silica-gel plates (HSGF254, Yantai Chemical Industry Research Institute, Yantai, China) with solvent system of CHCl<sub>3</sub>/MeOH (9:1, v/v) and the developed TLC plates were observed under a UV lamp at 254 nm or by heating after spraying with sulfuric acid-ethanol, 5:95 (v/v). The Fr.2 was subjected to another silica gel column eluted with CHCl<sub>3</sub>/MeOH (95:5-60:40, v/v) to give six fractions (Fr.2-1-Fr.2-6). The Fr.2-4 was further purified by semipreparative HPLC (Agilent 1100, Zorbax SB-C18, 5 µm,  $250 \times 9.4 \text{ mm}$  inner diameter; 1.5 ml min<sup>-1</sup>; 254 nm; Agilent, PaloAlto, CA, USA) eluting with CH<sub>3</sub>CN/H<sub>2</sub>O (20:80, v/v) to obtain compound 1 ( $t_{\rm R}$  24.68 min, 18.0 mg). The Fr.2-3 was separated by semi-preparative HPLC eluting with CH<sub>3</sub>CN/H<sub>2</sub>O (25:75, v/v) to afford compound 2 ( $t_R$  20.13 min, 14.2 mg). The Fr.1 was subjected to a Sephadex LH-20 (GE Healthcare, Glies, UK) column eluted with CHCl<sub>3</sub>/MeOH (1:1, v/v) and detected by TLC to give two subfractions (Fr.1-1-Fr.1-2). The Fr.1-2 was isolated by semi-preparative HPLC eluting with CH<sub>3</sub>CN/  $H_2O$  (35:65, v/v) to give compound 3 ( $t_R$  25.06 min, 23.5 mg). <sup>1</sup>H and <sup>13</sup>C NMR spectra were measured with a Bruker DRX-400 (400 MHz for  ${}^{1}$ H and 100 MHz for  ${}^{13}$ C) spectrometer (Bruker, Rheinstetten, Germany). The ESI-

MS and HR-ESI-MS spectra were taken on a Q-TOF Micro LC-MS-MS mass spectrometer (Waters Co, Milford, MA, USA).

Compound 1 was isolated as colorless oil with  $\left[\alpha\right]_{D}^{25} + 125$ (c 0.03, EtOH) and UV (EtOH)  $\lambda_{max}$  nm (log  $\varepsilon$ ): 233 (4.02). Its molecular formula was determined to be C23H35NO9 by HRESIMS at m/z 492.2207 [M + Na]<sup>+</sup> (calcd as 492.2204 for  $C_{23}H_{35}NO_9Na$ ) and NMR data (Table 1). In the IR spectrum of 1, absorption at 3447, 3197, and  $1689 \text{ cm}^{-1}$  indicated the presence of hydroxyl, imide, and carbonyl groups, respectively. Analysis of <sup>1</sup>H NMR spectrum (Table 1) of 1 revealed the presence of three olefinic protons at  $\delta_{\rm H}$  5.19 (1 H, br d, J = 9.8 Hz), 5.48 (1 H, m), 5.82 (1 H, br d, J = 11.6 Hz), one anomeric proton at  $\delta_{\rm H}$  4.87 (1 H, d, J = 3.9 Hz), one oxygenated methylene at  $\delta_{\rm H}$  3.64 (1 H, dd, J = 11.9, 5.3 Hz), 3.78 (1 H, dd, J = 11.9, 2.1 Hz), five oxygenated methine protons from  $\delta_{\rm H}$  3.27 to  $\delta_{\rm H}$  4.19, two olefinic methyls at  $\delta_{\rm H}$  1.77 (3 H, dd, J = 7.2, 2.6 Hz), 1.86 (3 H, d, J = 1.2 Hz), one doublet aliphatic methyl at  $\delta_{\rm H}$  1.14 (3 H, d, J = 6.8 Hz). The <sup>13</sup>C NMR and DEPT135 spectra (Table 1) of 1 showed 23 resonances attributable to one carbonyl carbon at  $\delta_{\rm C}$  212.1, two amide carbonyl carbons at  $\delta_{\rm C}$  175.4 and 175.4, three  $sp^2$ methines at  $\delta_{\rm C}$  125.8, 129.7, 134.1, one  $sp^2$  quaternary carbon at  $\delta_{\rm C}$  136.7, one anomeric carbon at  $\delta_{\rm C}$  99.1, five oxygenbearing aliphatic methines between 71.6 and 75.0 ppm, one oxygenated methylene at  $\delta_{\rm C}$  62.5, two aliphatic methines at  $\delta_{\rm C}$ 28.2, 48.2, four aliphatic methylenes at  $\delta_{\rm C}$  37.9, 39.2, 41.4, 44.8, and three methyl carbons at  $\delta_{\rm C}$  15.0, 16.7, 17.5. Comparison of the <sup>1</sup>H and <sup>13</sup>C NMR data (Table 1) of **1** with those of 3 revealed significant similarities. The differences between 1 and 3 were that 1 showed six extra  $^{13}$ C resonances. The six extra <sup>13</sup>C resonances were postulated to glucose moiety according to one doublet anomeric proton ( $\delta_{\rm H}$  4.87), one oxygenated methylene ( $\delta_{\rm H}$  3.64, 3.78) and four oxygenated methine protons. The relatively small  ${}^{3}J_{\rm HH}$  value (3.9 Hz) of the anomeric proton suggested an  $\alpha$  linkage [9]. The linkage of the glucose to the aglycone was established by the HMBC correlation (Fig. 2) from H-1" to C-2. The NOESY correlations (Fig. 2) between H-5 and H<sub>3</sub>-12, H-6 and H-8 demonstrated the geometry of  $\Delta^{6,7}$  was *E*. In the <sup>1</sup>H NMR spectrum of 1, the coupling constant between H-8 and H-9 was 11.6 Hz, indicating the geometry of  $\Delta^{8,9}$  was Z. Furthermore, the presence of glucose was evidenced by the acid hydrolysis. Compound 1 (2.5 mg) was dissolved in 2 ml of 2 M HCl and heated for 2 h at 80 °C, followed by neutralization with NaHCO<sub>3</sub>. The reaction mixture was extracted with CHCl<sub>3</sub> to separate a sugar moiety-containing aqueous fraction from the aglycone-containing fraction. The aqueous fraction was identified by cochromatography with authentic glucose on TLC analysis using ethyl acetate/pyridine/glacial acetic acid/ H<sub>2</sub>O (8: 5: 1: 1.5, v/v) as a developing solvent. Spots were detected by heating after spraying with sulfuric acid-ethanol (5:95, v/v). The identical  $R_{\rm f}$  values of the aqueous fraction

Position	1 (in CD <sub>3</sub> OD)		2 (in CD <sub>3</sub> OD)		3 (in CDCl <sub>3</sub> )
	$\delta_{\rm H} (J \text{ in Hz})$	$\delta_{ m C}$	$\delta_{\rm H} (J \text{ in Hz})$	$\delta_{ m C}$	$\delta_{\rm H}$ ( <i>J</i> in Hz)
1	1.50 m 1.73 m	41.4	1.51 m1.56 m	42.9	1.29 m 1.54 m
2	4.19 m	72.6	4.20 m	66.8	4.08 m
3	2.72 dd (17.6, 7.5)	44.8	2.81 dd (16.2, 4.6)	46.3	2.55 m
	2.96 dd (17.6, 4.6)		2.98 dd (16.2, 7.6)		2.64 m
4		212.1		203.2	
5	3.55 m	48.2		137.2	3.62 m
6	5.19 br d (9.8)	129.7	6.99 s	144.7	5.12 d (9.6)
7		136.7	133.5		
8	5.82 br d (11.6)	134.1	5.63 d (8.2)	140.4	5.74 d (11.7)
9	5.48 m	125.8	4.66 m	65.2	5.42 m
10	1.77 dd (7.2, 1.8)	15.0	1.28 d (6.3)	23.4	1.72 dd (7.2, 1.7)
11	1.14 d (6.8)	16.7	1.95 s	13.2	1.11 d (6.8)
12	1.86 d (1.2)	17.5	1.92 s	16.7	1.80 d (1.2)
1''		175.4		175.6	
2'	2.31 m 2.60 m	39.2	2.36 m 2.75 m	38.0	2.24 m 2.70 m
3'	2.35 m	28.2	2.38 m	28.7	2.40 m
4′	2.31 m 2.77 m	37.9	2.38 m2.68 m	39.2	2.24 m 2.70 m
5'		175.4		175.5	
1″	4.87 d (3.9)	99.1			
2″	3.34 m	73.2			
3″	3.27 t (12.4)	71.6			
4″	3.57 m	74.5			
5″	3.52 m	75.0			
6″	3.78 dd (11.9, 2.1)	62.5			
	3.64 dd (11.9, 5.3)				

 Table 1 The NMR spectroscopic data of compounds 1–3

with that of authentic glucose indicated that the sugar moiety of 1 was glucose. The aglycone-containing fraction was subjected to reverse phase HPLC for analysis, with a Zorbax B-C18 column (Agilent 1100, 250 × 9.4 mm inner diameter, 5 µm), mobile phase of CH<sub>3</sub>CN/H<sub>2</sub>O (35:65, v/v), flow rate at 1.5 ml min<sup>-1</sup>, and detection wavelength at 220 nm. Under these conditions, the aglycone-containing fraction gives peak at  $t_{\rm R}$  (min) = 25.06. The peak of the known compound 9-methylstreptimidone (3) was detected at  $t_{\rm R}$  (min) = 25.11. The retention time of the aglycone moiety of 1 was in good agreement with 3, which suggested that the aglycone moiety of 1 was 9-methylstreptimidone. In order to determine the absolute configuration of the glucose moiety in 1, the sugar residue was dissolved in pyridine (3 ml) containing L-cysteine methyl ester hydrochloride (1 mg) and heated at 60 °C for 1 h. A total of solution of O-torylisothiocyanate (25 µl) was added to the mixture, which was heated at 60 °C for a further 1 h. The mixture was analyzed by reversed-phase HPLC (Amethyst C18-H, 5  $\mu$ m, 250 × 4.6 mm inner diameter; 0.8 ml min <sup>-1</sup>; 250 nm) at 35 °C eluting with CH<sub>3</sub>CN/H<sub>2</sub>O (25:75, v/v). Under these conditions, standard sugar gave peak at  $t_{\rm R}$  (min)

= 21.658 for D-glucose. The peak of the sugar residue was detected at  $t_{\rm R}$  (min) = 21.789, which identified as D-glucose by comparison with the retention time of the authentic sample [10–12].

Compound 2 was isolated as pale yellowish oil with optical rotation of  $[\alpha]_D^{25} + 105$  (c 0.03, EtOH) and UV (EtOH)  $\lambda_{max}$  nm (log  $\varepsilon$ ): 276 (4.10). HR-ESI-MS showed a molecular ion peak at m/z 346.1625  $[M + Na]^+$  (calcd for C<sub>17</sub>H<sub>25</sub>NO<sub>5</sub>Na, 346.1625), indicating a molecular formula of C<sub>17</sub>H<sub>25</sub>NO<sub>5</sub>. In the IR spectrum of **2**, absorption at 3419 and  $1684\,\mathrm{cm}^{-1}$  indicated the presence of hydroxyl and carbonyl groups, respectively. Analysis of <sup>1</sup>H NMR spectrum (Table 1) of 2 revealed the presence of two olefinic protons at  $\delta_{\rm H}$  5.63 (1 H, d, J = 8.2 Hz), 6.99 (1 H, s), two oxygenated methine protons at  $\delta_{\rm H}$  4.20 (1 H, m), 4.66 (1 H, m), two olefinic methyl carbons at  $\delta_{\rm H}$  1.92 (3 H, s), 1.95 (3 H, s), one doublet aliphatic methyl at  $\delta_{\rm H}$  1.28 (3 H, d, J = 6.3 Hz). The <sup>13</sup>C NMR and DEPT135 spectra (Table 1) of 2 showed 17 resonances attributable to one carbonyl carbon at  $\delta_{\rm C}$  203.2, two amide carbonyl carbons at  $\delta_{\rm C}$  175.5 and 175.6, two  $sp^2$  methines at  $\delta_{\rm C}$  140.4, 144.7,




Fig. 2 Key  $^1\mathrm{H}\textsc{-1}\mbox{H}$  COSY, HMBC, and NOESY correlations of compounds 1 and 2

two sp<sup>2</sup> quaternary carbons at  $\delta_{\rm C}$  133.5, 137.2, one aliphatic methine at  $\delta_{\rm C}$  28.7, two oxygenated methines at  $\delta_{\rm C}$  65.2, 66.8, four methylenes at  $\delta_{\rm C}$  38.0, 39.2, 42.9, 46.3, and three methyl resonances at  $\delta_{\rm C}$  13.2, 16.7, 23.4. The complete assignment of all <sup>1</sup>H and <sup>13</sup>C NMR spectral data of 2 was subsequently accomplished by the <sup>1</sup>H-<sup>1</sup>H COSY, HSQC and HMBC spectra. The correlations between H-3'/H2-1/H-2/H<sub>2</sub>-3, H-8/H-9/H<sub>3</sub>-10 protons in the <sup>1</sup>H-<sup>1</sup>H COSY spectrum (Fig. 2) indicated the presence of two structural units of C-3'-C-3 and C-8-C-10. The observed HMBC correlations (Fig. 2) from H-2, H-6 to C-4, from H<sub>3</sub>-11 to C-4, C-5, C-6, from H<sub>3</sub>-12 to C-6, C-7, C-8 established the linkage of C-3'-C-10. A glutarimide ring was defined by two amide carbonyl carbons at  $\delta_{\rm C}$  175.5 and 175.6, which were coupled long range in an HMBC experiment to the protons (Table 1) of a four protons pair of methylene signals at  $\delta_{\rm H}$ 2.36 (1 H, m), 2.38 (1 H, m), 2.68 (1 H, m), 2.75 (1 H, m), which were in turn coupled in a <sup>1</sup>H-<sup>1</sup>H COSY spectrum to a single methine proton signal at  $\delta_{\rm H}$  2.38 (1 H, m) [13]. On the basis of the above spectroscopic data, a gross structure of 2 was established (Fig. 1). The NOESY correlation (Fig. 2) between H<sub>3</sub>-11 and H<sub>3</sub>-12 demonstrated the geometry of  $\Delta^{5,6}$  was E. The geometry of  $\Delta^{7,8}$  was also assigned as E by the NOESY correlation between H-6 and H-8. The absolute configuration of 2 was determined by the





Fig. 3  $\Delta\delta$  values for the MTPA esters (1a, 1b);  $\Delta\delta$  (ppm) =  $\delta_{S1a} - \delta_{R1b}$ 



**Fig. 4**  $\Delta\delta$  values for the MTPA esters (2a, 2b);  $\Delta\delta$  (ppm) =  $\delta_{S2a} - \delta_{R2b}$ 

modified Mosher's method [14, 15]. To a solution of compound 2 (2.5 mg) in dry pyridine (200 µL) was added (-)-MTPA chloride  $(15 \,\mu l)$ , and the solution was stirred at room temperature for 1 h. The reaction mixture was fractionated by semi-preparative HPLC eluting with CH<sub>3</sub>CN/ H<sub>2</sub>O (80:20, v/v) to afford (S)-MTPA esters 1a ( $t_R$ 19.82 min, 1.2 mg) and **2a** ( $t_{\rm R}$  20.39 min, 1.0 mg). In the same way, by using (+)-MTPA chloride, the compound 2 (2.5 mg) was converted into a mixture. The mixture was isolated by semi-preparative HPLC eluting with CH<sub>3</sub>CN/  $H_2O$  (85:15, v/v) to obtain (R)-MTPA esters 1b ( $t_R$  26.18 min, 1.0 mg) and **2b** ( $t_R$  27.43 min, 1.0 mg). Based on the MTPA determination rule, calculating  $\Delta \delta$  (ppm) =  $\delta_{S 1a}$  - $\delta_{R1b}$  (Fig. 3), the absolute configuration at C-2 was assigned as R and the absolute configuration at C-9 was assigned as *R*. However, calculating  $\Delta \delta$  (ppm) =  $\delta_{S 2a} - \delta_{R 2b}$  (Fig. 4), the absolute configuration at C-2 was assigned as R and the absolute configuration at C-9 was assigned as S. It showed that 2 was a C-9 epimeric mixture. Chiral HPLC analysis of 2 with a CElluose-C column and mobile phase of CO<sub>2</sub>/MeOH further indicated that 2 was the epimeric mixture in a ratio of ~3:2.

Compound **3** was isolated as pale yellowish oil. Its structure was elucidated as 9-methylstreptimidone by analysis of its <sup>1</sup>H NMR and ESI-MS spectral data (Table 1) and comparison with literature values [16].

The cytotoxicity of **1** and **2** was assayed for growthinhibition activity in vitro against three human tumor cell lines, human erythroleukemia cell line K562, human breast cancer cell line MCF-7, and human colon carcinoma cell line HCT-116 according to the CCK8 colorimetric method as reported in our previous papers [17, 18] using

Table 2 Cytotoxic activity of 1 and 2 against selected human tumor cell lines

Compounds	$IC_{50} \ (\mu g \ m l^{-1})$				
	K562	MCF-7	HCT-116		
1	28.37	28.79	34.83		
2	36.47	34.68	36.76		
doxorubicin	1.17	0.79	0.45		

doxorubicin as positive control. The results (Table 2) demonstrated that the two new compounds possessed moderate cytotoxic activity towards the three tumor cell lines.

Acknowledgements This work was supported in part by grants from the National Key Research and Development Program of China (No. 2017YFD0201606).

#### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

- Kim BS, Moon SS, Hwang BK. Isolation, antifungal activity, and structure elucidation of the glutarimide antibiotic, streptimidone, produced by *Micromonospora coerulea*. J Agri Food Chem. 1999;47:3372–80.
- Allen MS, Becker AM, Rickards RW. The glutarimide antibiotic 9-methylstreptimidone: structure, biogenesis and biological activity. Aust J Chem. 1976;29:673–9.
- Whiffen AJ, Bohonos N, Emerson RL. The production of an antifungal antibiotic by *Streptomyces griseus*. J Bacteriol. 1946;52:610–1.

- Johnson F, Starkovsky NA, Gurowitz WD. Glutarimide antibiotics. VII. The synthesis of *dl*-neocycloheximide and the determination of the cyclohexanone ring stereochemistry of cycloheximide, its isomers, and inactone. J Am Chem Soc. 1965;87:3492–3500.
- Nakae K, et al. Migrastatin, a novel 14-membered lactone from *Streptomyces* sp. MK929-43F1. J Antibiot. 2000;53:1228–30.
- Shan D, et al. Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice. Proc Natl Acad Sci USA. 2005;102:3772–6.
- 7. Ji X, et al. Synthesis and antiviral activities of synthetic glutarimide derivatives. Chem Pharm Bull. 2010;58:1436–41.
- Ishikawa Y, Tachibana M, Matsui C, Obata R, Umezawa K, Nishiyama S. Synthesis and biological evaluation on novel analogs of 9-methylstreptimidone, an inhibitor of NF-κB. Bioorg Med Chem Lett. 2009;19:1726–8.
- Patra S, et al. Structural characterization of an immunoenhancing heteropolysaccharide isolated from hot water extract of the fresh leaves of *Catharanthus rosea*. Carbohyd Polym. 2010;81:584–91.
- Tanaka T, Nakashima T, Ueda T, Tomii K, Kouno I. Facile discrimination of aldose enantiomers by reversed-phase HPLC. Chem Pharm Bull. 2007;55:899–901.
- Bang S, et al. New aromatic compounds from the fruiting body of Sparassis crispa (Wulf.) and their inhibitory activities on PCSK 9 mRNA expression. J Agri Food Chem. 2017;65:6152–7.
- Zheng Q, Koike K, Han LK, Okuda H, Nikaido T. New biologically active triterpenoid saponins from *Scabiosa tschiliensis*. J Nat Prod. 2004;67:604–13.
- Hochlowski JE, Whittern DN, Hill P, Mcalpine JB. Dorrigocins: novel antifungal antibiotics that change the morphology of *ras*transformed NIH/3T3 cells to that of normal cells. II. isolation and elucidation of structure. J Antibiot. 1994;47:870–4.
- Kubota NK, et al. Two new analogues of the cytotoxic substance BE-52211 from *Streptomyces* sp. J Nat Prod. 2004;67:85–7.
- 15. Ngo QT, et al. Lactones from the pericarps of *Litsea japonica* and their anti-inflammatory activities. Bioorg Med Chem Lett. 2018;28:2109–15.
- Cheng C, Liu Q, Chen L, Jin W, Si S, Li D. Isolation, structure determination and biological activity of a new glutarimide antibiotic, S632A3. J Asian Nat Prod Res. 2006;8:55–60.
- Wang J, Zhang H, Yang X, Zhou Y, Wang H, Bai H. HS071, a new furan-type cytotoxic metabolite from *Streptomyces* sp. HS-HY-071. J Antibiot. 2008;61:623–6.
- Wang J, et al. Five new epothilone metabolites from *Sorangium* cellulosum strain So0157-2. J Antibiot. 2009;62:483–7.